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Abstract
Background: Multiple lines of evidence suggest that genetic factors contribute to stroke recovery. The matrix
metalloproteinases -2 (MMP-2) and -9 (MMP-9) are modulators of extracellular matrix components, with important
regulatory functions in the Central Nervous System (CNS). Shortly after stroke, MMP-2 and MMP-9 have mainly
damaging effects for brain tissue. However, MMPs also have a beneficial activity in angiogenesis and neurovascular
remodelling during the delayed neuroinflammatory response phase, thus possibly contributing to stroke functional
recovery.
Methods: In the present study, the role of MMP-2 and MMP-9 genetic variants in stroke recovery was investigated
in 546 stroke patients. Functional outcome was assessed three months after a stroke episode using the modified
Rankin Scale (mRS), and patients were classified in two groups: good recovery (mRS ≤ 1) or poor recovery (mRS>1).
Haplotype tagging single nucleotide polymorphisms (SNPs) in the MMP-2 (N = 21) and MMP-9 (N = 4) genes were
genotyped and tested for association with stroke outcome, adjusting for significant non-genetic clinical variables.
Results: Six SNPs in the MMP-2 gene were significantly associated with stroke outcome (0.0018<P < 0.0415), two
of which survived the Bonferroni correction for multiple testing. In the subset of ischemic stroke patients,
association of five of these SNPs remained positive (0.0042<P < 0.0306). No significant associations were found for
the MMP-9 gene.
Conclusions: The results presented strongly indicate that MMP-2 genetic variants are an important mediator of
functional outcome after stroke.
Background
While remaining one of the most common causes of
death worldwide, stroke is also a leading cause of signifi-
cant disability: after a first stroke event, 50-70% of
stroke patients regain functional independence, but 15-
30% are permanently disabled and 20% require institu-
tional care at 3 months after onset [1]. Clinical and
demographic factors can influence stroke outcome. In
addition, genetic factors are likely to have an impact in
stroke recovery processes and outcome: family history of
stroke is associated with stroke outcome [2,3] and many
animal models of stroke implicate genes that regulate
angiogenesis, neuronal regeneration and proliferation,
and neuroinflammation, in stroke recovery [4-7].
Several lines of evidence suggest that matrix metallo-
proteinases (MMPs) are fundamental players in stroke
recovery. These molecules belong to a family of zinc-
dependent endopeptidases that modulate extracellular
matrix (ECM) components in many Central Nervous
System (CNS) developmental and regenerative processes
such as neurogenesis, axonal growth and regeneration,
and myelin formation. The expression and activity of
MMPs is tightly regulated. Most MMPs require proteo-
lytic processing by proteases or other MMPs to become
activated, and can be inhibited by tissue inhibitors of
metalloproteinases (TIMPs). Dysregulated MMP activity
will lead to uncontrolled degradation of ECM and basal* Correspondence: avicente@igc.gulbenkian.pt
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lamina proteins, with serious harmful effects for the
blood-brain barrier (BBB) integrity and neuroinflamma-
tory or neurotoxic consequences [8,9]. Such dysregula-
tion of MMPs is known to occur after stroke, leading to
a degradation of the neurovascular matrix, disrupting
cell-matrix homeostasis and weakening the BBB, and
thus contributing to cell death, neurotoxicity, edema
and hemorrhage [9,10]. The variation profiles of MMPs
in blood after a stroke event [11,12] suggest that these
molecules can eventually be used as biomarkers for
brain damage and neurological outcome, while their
contribution to tissue destruction renders MMPs inhibi-
tors potentially interesting therapeutic targets for stroke.
Emerging studies, however, indicate that MMPs may
also have a beneficial activity in angiogenesis and neuro-
vascular remodelling during the delayed neuroinflamma-
tory response phase after stroke, possibly contributing to
stroke functional recovery [9]. While inhibition of MMP
activity has consistently been demonstrated to be effective
in reducing edema, infarct size and hemorrhagic transfor-
mation, some studies suggest the existence of a time win-
dow for these beneficial effects to take place [13,14].
In the present study we tested the impact of genetic
variants in MMP-2 and MMP-9 in stroke recovery, in a
population sample of 546 patients evaluated for stroke
outcome at three months after the stroke event.
Methods
Participants in the present study were recruited in the
context of a wider research project to evaluate stroke
risk factors in a Portuguese population sample, which
enrolled first-ever stroke patients under 65 years of age
through Neurology and Internal Medicine Departments
of several hospitals in Portugal. Stroke was defined as a
focal neurological deficit of sudden or rapid onset last-
ing more than 24 hours, and classified into ischemic or
intracerebral hemorrhage based on brain imaging (com-
puted tomography and/or magnetic resonance imaging).
The diagnosis of stroke was confirmed by a neurologist.
Demographic characteristics (age and gender), informa-
tion on previous vascular risk factors and comorbid con-
ditions (diabetes mellitus, hypertension, cardiac disease,
dyslipidemia, obesity), life-style risk factors (smoking
status, alcohol consumption, physical inactivity and
others), and detailed clinical data during hospitalization,
including neurological symptoms, complications and
interventions, were collected for the majority of patients.
Occurrence of aphasia, neglect, paresis, gaze paresis,
dysphagia, permanent consciousness disturbance, urin-
ary incontinence and medical and neurological compli-
cations were clinical parameters indicative of stroke
severity. Stroke outcome at discharge and at three
months was assessed, by direct interview, using the
modified Rankin Scale (mRS).
For the present study, 568 patients with relevant clini-
cal data and a DNA sample were available. Eight
patients had a second stroke event after enrolment,
affecting patient recovery, and were thus excluded. Of
the remaining 560, 14 did not return after discharge for
the three months evaluation, and therefore only 546
patients were included in the analysis. Patients were
classified in two groups, according to their mRS at three
months: patients with mRS ≤ 1 were assigned to the
“good recovery” group and patients with mRS>1 were
assigned to the “poor recovery” group (handicapped
patients). 276 individuals were included in the good
recovery group (63.0% males and 37.0% females) and
270 in the poor recovery group (64.4% males, 35.6%
females). The poor recovery group included 12 patients
who died before the three months evaluation (seven of
them before hospital discharge, and five others after dis-
charge). Genetic power calculations were performed
using the CaTS software [15].
The study was approved by the Ethics Committee of
Instituto Nacional de Saúde Dr. Ricardo Jorge and other
hospitals involved, subjects gave informed consent and
procedures followed were in accordance with institu-
tional guidelines.
Single nucleotide polymorphisms (SNPs) within the
MMP-2 and MMP-9 genes and up to 5 kb of the flank-
ing regions were selected using the Haploview software
(v4.0) [16], based on their tagging potential (HapMap
Release 21/phase II July 2006). 4 SNPs in MMP-9 and
20 SNPs in MMP-2 were genotyped using the Seque-
nom iPLEX assays with allele detection by mass spectro-
scopy, using Sequenom MassARRAY technology
(Sequenom, San Diego, USA) and following the manu-
facturer’s protocol. Primer sequences were designed
using Sequenom’s MassARRAY Assay Design 3.0 soft-
ware. 1 SNP in MMP-2 was genotyped using TaqMan®
Pre-Designed SNP Genotyping Assays, in an ABI
PRISM 7900HT Sequence Detector System (Applied
Biosystems, Foster City, USA). Extensive quality control
was performed using eight HapMap individuals, dupli-
cated samples within and across genotyping plates,
Mendelian segregation in three pedigrees and no-tem-
plate samples. Call rates <90% and deviation from
Hardy-Weinberg equilibrium led to SNP exclusion from
the analysis. 2 SNPs in MMP-9 failed quality control
and were substituted. In total, 21 MMP-2 SNPs and 4
MMP-9 SNPs were analysed.
The effect of discrete and continuous non-genetic
variables on stroke outcome at three months was deter-
mined using the Pearson c2 test and Mann-Whitney
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test, respectively. These included age, gender, stroke risk
factors as well as data on clinical variables collected dur-
ing hospitalization (like occurrence of paresis, aphasia
and medical complications). Variables with a P < 0.25 in
univariate analysis or of particular clinical relevance
were included in a logistic regression model using for-
ward selection [17] and were maintained in the model if
they were associated at a P ≤ 0.05 level with stroke out-
come. Logistic regression analyses were then used to
determine the effect of each genetic variable on stroke
outcome after adjustment for those significant non-
genetic variables. Odds ratio (OR) and 95% confidence
intervals (95% CI) were computed for the log-additive
model. Univariate and logistic regression analyses were
performed using MASS and SNPassoc packages of the R
software [18] (v2.6.0). The Gabriel et al. (2002) [19]
default method of the Haploview software [16] (v4.0)
was used to determine haplotype blocks in the MMP-2
and MMP-9 genes. Since recovery processes may be
regulated differently in ischemic and hemorrhagic stroke
patients, we performed the same analyses in the subset
of ischemic stroke patients. The small number of
hemorrhagic stroke patients (N = 105) precluded the
independent analysis of this subset.
Significant associations in individual SNP analysis
were corrected for multiple testing using the Bonferroni
method. The alternative SNPSpD approach, based on
the spectral decomposition (SpD) of matrices of pairwise
linkage disequilibrium (LD) between SNPs was also
applied [20]. Since some of the 21 SNPs genotyped in
the MMP-2 gene are in LD with each other in our sam-
ple, we used the SNPSpD approach to estimate the
effective number of independent SNPs in our sample for
multiple testing corrections.
Results
Clinical and demographic characteristics of the popula-
tion sample are presented in Table 1. Univariate analy-
sis showed that type of stroke and six clinical features
indicative of stroke severity - occurrence of aphasia,
urinary incontinence, paresis, consciousness distur-
bance, medical and neurological complications during
hospitalization - were significant predictors of poor
outcome. Sex ratio, age, and stroke risk factors were
similar between the poor and good recovery groups,
and approximately the same proportion of patients was
being treated for hypertension in either group (34.0%
and 34.6% in the good and poor recovery groups,
respectively). Assuming an additive genetic model and
disease allele frequency of 30%, our sample was 82%
powered to detect a genotype relative risk of 1.5 with a
type I error of 5%.
Of 21 MMP-2 SNPs, six were associated with stroke
outcome at three months under a log-additive model
(0.0018<P < 0.0415) after adjusting for the significant
covariates in a multivariate model: history of hyperten-
sion, type of stroke, occurrence of aphasia, paresis, con-
sciousness disturbance and medical complications
during hospitalization (Table 2; see Additional file 1).
History of hypertension, although not associated in the
univariate analysis, became significant in the multivari-
ate model before inclusion of genetic variants, and was
therefore included in the final regression model. SNPs
rs2241145 and rs1992116 remained significantly asso-
ciated with stroke outcome after Bonferroni correction
for multiple testing (OR [95%CI] = 1.66 [1.20-2.30], cor-
rected P = 0.0439, and OR [95%CI] = 1.67 [1.20-2.31],
corrected P = 0.0385, respectively). Two haplotypes (one
of which rare) were nominally associated with stroke
outcome at three months (Table 3, Figure 1A; see Addi-
tional file 2).
The hypothesis that the recovery processes after
ischemic and hemorrhagic stroke may be different and
regulated by different sets of genes [21,22] led us to ana-
lyze the ischemic stroke subset independently. The hae-
morrhagic subset was too small for independent analysis
(N = 105). In the ischemic stroke sample, five out of the
previously associated SNPs in the MMP-2 gene
remained significantly associated with stroke outcome at
three months under a log-additive model (0.0042<P <
0.0306), after adjusting for the same significant covari-
ates (excluding type of stroke) (Table 2; see Additional
file 1). ORs for these SNPs in this subset were similar to
the overall study sample. None of the SNPs remained
significant after Bonferroni correction for multiple test-
ing. However, when the SNPSpD method was used, tak-
ing into account regional LD patterns and therefore
the number of SNPs which are effectively independent,
the two SNPs that survived Bonferroni correction in the
whole sample remained significant for the ischemic
stroke subset (rs2241145 and rs1992116) (see Additional
file 1). Four additional MMP-2 SNPs were nominally
associated with ischemic stroke outcome at three
months (0.0162<P < 0.0412, Table 2). Only one haplo-
type in MMP-2 was also associated (Table 3; see Addi-
tional file 2).
OR analysis indicates that, for the majority of signifi-
cantly associated SNPs (including rs2241145 and
rs1992116), carriers of the minor allele (less frequent
allele) are significant predictors of poor outcome
(OR>1); only for rs243842 in the whole population sam-
ple, and for rs857403 and rs183112 in the ischemic sub-
set, carriers of the minor allele show an improved
chance of good recovery from stroke (OR<1).
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In the MMP-9 gene, one rare haplotype was associated
with stroke outcome in the overall population sample
(P = 0.0065, Table 3, Figure 1B; see Additional file 2),
but no independent association was found for any of the
four tested SNPs (see Additional file 1). No SNP or hap-
lotype in the MMP-9 gene was associated with stroke
outcome at three months in the ischemic subset (see
Additional files 1 and 2).
None of the tested SNPs were associated with hyper-
tension, indicating that the MMP-2 effect on recovery
was not mediated by its role on vascular structure (data
not shown).
Two of the MMP-2 SNPs (rs1053605 and rs243849)
are located in exonic regions of the MMP-2 gene
(exons 5 and 7, respectively), two SNPs (rs243866 and
rs243865) are located upstream of the gene, and six
SNPs are intronic (Figure 1A). Both nucleotide transi-
tions in the exonic SNPs are silent. To investigate pos-
sible functional consequences for gene transcription of
the two upstream SNPs (rs243866 and rs243865) and
the two intronic SNPs that survived correction for
multiple testing (rs2241145 and rs1992116), we con-
ducted a bioinformatics search for putative transcrip-
tion factor binding sites. The A allele of the upstream
SNP rs243866 lies in the core of a sequence with high
similarity to the matrix for two binding factors, the
IPF1 (insulin promoter factor 1), and the POU5F1
(POU domain class 5 transcription factor 1). Both pro-
teins are transcription activators. Since the AA and
AG genotypes are more frequent in the poor recovery
group, we can hypothesize that the presence of the A
allele may lead to an increased transcription of the
MMP-2 gene, and thus explain the negative impact on
stroke recovery observed in this population sample.
The presence of the T allele in the upstream rs243865
SNP forms a sequence with high similarity to the
matrix for the PLZF binding factor (promyelocytic leu-
kemia zinc finger protein), while the sequence contain-
ing the C allele has a stronger similarity with the
matrix for the VDR/RXR (vitamin D hormone recep-
tor/retinoid × receptor) heterodimer. However, both
transcription factors act as repressors, and therefore
these findings are more difficult to interpret. The
rs2241145 and rs1992116 intronic SNPs did not con-
tain sequences for any known putative transcription
factor binding sites.
Discussion
In the present study we show that MMP-2 gene var-
iants are strongly associated with patient’s functional
Table 1 Demographic and clinical characteristics of stroke patients
Characteristic Good Recovery (mRS ≤ 1) Poor Recovery (mRS>1) P*
Age and Gender
Age, mean ± SD (yrs) 50.8 ± 9 52.5 ± 8.5 0.028
Gender (male), n/N (%) 174/276 (63.0) 174/270 (64.4) 0.734
Past History, n/N (%)
Hypertension 159/241 (66.0) 143/240 (59.6) 0.147
Diabetes 36/259 (13.9) 47/246 (19.1) 0.115
Cardiac Disease 37/264 (14.0) 43/257 (16.7) 0.390
Sroke type, n/N (%)
Ischemic stroke 238/276 (86.2) 193/270 (71.5) -
Hemorrhagic stroke 33/276 (12.0) 72/270 (26.7) -
Unknow type of stroke 5/276 (1.8) 5/270 (1.9) -
Stroke Features, n/N (%)
Aphasia 53/258 (20.5) 98/250 (39.2) 4.23 × 10-6
Neglect 11/266 (4.1) 19/240 (7.9) 0.072
Dysphagia 15/270 (5.6) 25/251 (10.0) 0.059
Urinary Incontinence 5/272 (1.8) 15/251 (6.0) 0.014
Paresis 203/273 (74.4) 244/269 (90.7) 5.59 × 10-7
Consciousness disturbance 21/275 (7.6) 59/265 (22.3) 1.72 × 10-6
Medical complications 18/265 (6.8) 82/254 (32.3) 1.83 × 10-13
Neurologic complications 14/274 (5.1) 39/267 (14.6) 2.03 × 10-4
*Mann-Whitney test or c2 test.
SD - standard deviation, yrs - years.
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Table 2 Genotype frequency distribution and association with stroke outcome at three months for MMP-2 SNPs
Whole sample* Ischemic subset†
Genotype frequency Genotype frequency
SNP Genotype Good recovery,
n (%)
Poor recovery,
n (%)
OR [95%CI] P Good recovery,
n (%)
Poor recovery,
n (%)
OR [95%CI] P
rs243866
G/G 142 (67.6) 117 (57.9) 1.67 [1.10-2.52] 0.0143 125 (67.6) 83 (56.8) 1.78 [1.13-2.80] 0.0128
A/G 66 (31.4) 76 (37.6) 59 (31.9) 55 (37.7)
A/A 2 (1.0) 9 (4.5) 1 (0.5) 8 (5.5)
rs243865
C/C 141 (67.8) 117 (57.9) 1.65 [1.09-2.50] 0.0162 124 (67.8) 83 (56.8) 1.76 [1.12-2.78] 0.0143
C/T 65 (31.2) 76 (37.6) 58 (31.7) 55 (37.7)
T/T 2 (1.0) 9 (4.5) 1 (0.5) 8 (5.5)
rs857403
A/A 124 (59.3) 138 (68.3) 0.71 [0.48-1.06] 0.0909 105 (57.1) 103 (70.5) 0.62 [0.40-0.97] 0.0349
T/A 75 (35.9) 56 (27.7) 70 (38) 37 (25.3)
T/T 10 (4.8) 8 (4.0) 9 (4.9) 6 (4.1)
rs1477017
A/A 100 (47.6) 81 (40.1) 1.42 [1.01-2.00] 0.0415 86 (46.5) 55 (37.7) 1.51 [1.04-2.20] 0.0306
G/A 91 (43.3) 98 (48.5) 82 (44.3) 72 (49.3)
G/G 19 (9.0) 23 (11.4) 17 (9.2) 19 (13)
rs17301608
C/C 94 (45.0) 75 (37.3) 1.40 [1.00-1.95] 0.0510 80 (43.5) 50 (34.5) 1.47 [1.01-2.12] 0.0412
C/T 94 (45.0) 100 (49.8) 85 (46.2) 73 (50.3)
T/T 21 (10.0) 26 (12.9) 19 (10.3) 22 (15.2)
rs1053605
C/C 188 (89.5) 170 (84.2) 2.02 [1.09-3.75] 0.0227 166 (89.7) 127 (87.0) 1.82 [0.93-3.58] 0.0817
C/T 22 (10.5) 28 (13.9) 19 (10.3) 16 (11.0)
T/T 0 (0.0) 4 (2.0) 0 (0.0) 3 (2.0)
rs2241145
G/G 79 (37.8) 56 (27.9) 1.66 [1.20-2.30] 0.0021‡ 68 (37.0) 39 (26.9) 1.67 [1.17-2.40] 0.0044
G/C 100 (47.8) 101 (50.2) 88 (47.8) 72 (49.7)
C/C 30 (14.4) 44 (21.9) 28 (15.2) 34 (23.4)
rs243849
C/C 131 (62.7) 143 (71.5) 0.70 [0.46-1.07] 0.0948 112 (60.9) 108 (75) 0.59 [0.36-0.96] 0.0314
T/C 70 (33.5) 52 (26.0) 65 (35.3) 33 (22.9)
T/T 8 (3.8) 5 (2.5) 7 (3.8) 3 (2.1)
rs183112
G/G 134 (64.1) 145 (72.9) 0.66 [0.43-1.03] 0.0669 115 (62.5) 110 (76.9) 0.54 [0.32-0.90] 0.0162
A/G 70 (33.5) 51 (25.6) 65 (35.3) 32 (22.4)
A/A 5 (2.4) 3 (1.5) 4 (2.2) 1 (0.7)
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disability at three months after stroke onset, in a large
Portuguese population sample. Given the possible
genetic heterogeneity in recovery processes after
hemorrhagic and ischemic stroke [21,22], we also ana-
lysed the association of this gene with stroke outcome
in the restricted subgroup of ischemic stroke patients.
All but one MMP-2 gene variants associated with
stroke in the overall population sample remained asso-
ciated with ischemic stroke in this smaller subset.
Additional markers were associated only in this subset,
possibly reflecting the increased genetic homogeneity
of the ischemic group in terms of recovery processes.
Associated SNPs in the ischemic subset did not, how-
ever, withstand Bonferroni correction for multiple test-
ing. This could reflect the reduction in power due to
the smaller sample size in the restricted analysis and/
or the overcorrection for the false positive rate that is
the main frequent criticism for this method. In fact,
the alternative SNPSpD approach [20], which takes
into account LD patterns between genotyped SNPs in
the tested population, may be more appropriate since
the 21 genotyped MMP-2 SNPs are not independent;
with this approach, the significance of association of
two specific SNPs with stroke, in the ischemic subset
or in the overall population sample, was retained after
multiple testing correction. The association results
after multiple testing correction, using the stringent
Bonferroni method or the SNPSpD approach, strongly
support a role for MMP-2 in stroke recovery. Valida-
tion through replication in a larger sample set by other
groups is now advisable.
A limitation of the present study was the lack of
availability of the National Institute of Health Stroke
Scale (NIHSS) for these patients. To control for the
effect of the severity of stroke in patients’ outcome, we
performed a logistic regression analysis using, as cov-
ariates, individual clinical variables associated with
stroke clinical severity in our sample. Each selected
variable was entered in the logistic regression model to
identify those behaving as clinical predictors of stroke
outcome. While this approach may not be as compre-
hensive as a widely used severity scale, it allowed us to
include in the analysis parameters that reflect the
severity of the event and, to a certain extent, patient’s
status at baseline.
While subject of controversy, the cut-off for the good
and poor recovery groups was set between 1 and 2
because we chose to focus on a non-handicaped recovery
group. According to Weisscher et al. (2008) [23], there is
a clear lag on performance of outdoor activities between
mRS 1 and 2, while between mRS 2 and 3 the major dif-
ference is the ability to perform complex activities of
daily life, and thus a more clearly defined good outcome
is given by setting the cut-off between mRS 1 and 2.
Multiple studies in animal models and humans have
shown that the actions of MMPs contribute to BBB dis-
ruption and brain cell death, early after a stroke event.
These damaging processes can be inhibited by MMP
inhibitors, leading to reductions in infarct volume and
significant improvements in behavioural scores compared
with controls [10]. However, fitting with their role in
development and regeneration, a beneficial influence of
MMPs in the recovery processes that occur in later stages
after a stroke event, including angiogenesis, remyelina-
tion, neural migration and general recovery of the neuro-
vascular unit has been shown [13,14,24,25]. At present,
we cannot dissect whether gene variation in MMP-2 is
more important for the damaging effects in the earlier
stages after stroke, or to the beneficial delayed responses,
or both. Functional studies will be required to answer
this question. However, the present findings may have
important implications. On one hand it challenges the
usefulness of MMP inhibitors for the treatment of stroke,
not only because the time window of usefulness is likely
limited, but also because it may depend on the indivi-
dual’s MMP-2 genotype. On the other hand, and given
Table 2: Genotype frequency distribution and association with stroke outcome at three months for MMP-2 SNPs
(Continued)
rs1992116
G/G 87 (41.6) 65 (32.3) 1.67 [1.20-2.31] 0.0018‡ 76 (41.3) 48 (33.1) 1.68 [1.17-2.42] 0.0042
A/G 97 (46.4) 94 (46.8) 86 (46.7) 67 (46.2)
A/A 25 (12.0) 42 (20.9) 22 (12.0) 30 (20.7)
95%CI - 95% Confidence Interval.
*OR [95%CI] and P for the log-additive genetic model after adjustment for significant covariates (history of hypertension, type of stroke, and occurrence of
aphasia, paresis, consciousness disturbance and complications during hospitalization).
†OR [95%CI] and P for the log-additive genetic model after adjustment for significant covariates (history of hypertension, and occurrence of aphasia, paresis,
consciousness disturbance and complications during hospitalization).
‡Significant result after Bonferroni correction.
Results were adjusted for significant covariates; Odds Ratio (OR)>1 indicates increased probability of poor recovery for the carriers of the minor allele; only
associated SNPs are shown.
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that MMP-2 has also been suggested to influence the risk
of hemorrhagic transformation upon recombinant tissue
plasminogen activator (tPA) therapy [26], it is a plausible
hypothesis that treatment outcome may also be asso-
ciated with MMP-2 gene variants. Further work needs to
be carried out to elucidate these questions.
Conclusions
The present study further reinforces the contribution of
MMPs for stroke recovery by showing that specific
MMP-2, but not MMP-9, gene variants influence stroke
outcome. Replication of these associations in larger
population samples, together with approaches that
Table 3 Haplotype frequency distribution of the MMP-2 and -9 genes, and association with stroke outcome
Whole sample Ischemic subset
Gene Haplotype Haplotype
frequency
Good
recovery
(%)
Poor
recovery
(%)
c2 P Haplotype
frequency
Good
recovery
(%)
Poor
recovery
(%)
c2 P
MMP-2 rs11643630-rs243866-rs243865 0.200 17.2 22.7 5.150 0.0233 0.198 16.8 23.5 6.125 0.0133
TAT
MMP-2 rs1477017-rs17301608-
rs1132896-rs1053605-
rs2241145-rs243849-rs243842-
rs183112
0.011 1.8 0.4 4.776 0.0289 0.014 2.1 0.6 3.372 0.0663
ACGCGTTG
MMP-9 rs8113877-rs3918253-
rs2236416
0.034 4.8 1.9 7.403 0.0065 0.038 4.9 2.4 3.680 0.0551
TCA
Only haplotypes with significant association results are presented.
Figure 1 Schematic diagrams of the MMP-2 (A) and MMP-9 (B) genes showing the location of the 13 exons (black boxes), the 5’ and 3’
untranslated regions (white boxes) and the pairwise r2 plots for the 21 genotyped SNPs in MMP-2 and 4 genotyped SNPs in MMP-9,
in our population sample. Markers associated with three months outcome are indicated. Linkage disequilibrium blocks were generated using
the Gabriel et al. [19] method.
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integrate evidence from multiple levels, including gene
expression and functional analysis, will contribute for
the validation of these results. Together with previous
observations, the study leads to the hypothesis that indi-
vidual variation in the MMP-2 gene may influence
stroke treatment outcome.
Additional file 1: Table 4: Association analysis results for MMP-2
and MMP-9 SNPs and stroke outcome. Association analysis results for
MMP-2 and MMP-9 SNPs and stroke outcome.
Additional file 2: Table 5: Association analysis results for MMP-2
and MMP-9 haplotypes and stroke outcome. Association analysis
results for MMP-2 and MMP-9 haplotypes and stroke outcome.
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